Introduction
If you've seen headlines saying PCOS has a new name - or your practitioner has started using an unfamiliar term - you haven't missed a new diagnosis or a change to your condition. In a landmark decision, polycystic ovary syndrome (PCOS) has officially been renamed polyendocrine metabolic ovarian syndrome (PMOS). It's the same condition you already know. What's changed is the name - and the change matters more than it might first appear, because of why it happened.
This article explains what the rename means for you, why a name that's stood for nearly 90 years was changed, and why - if you've ever felt your PCOS was about far more than your ovaries - the new name finally says out loud what many women have known all along.
First, the reassurance: your condition hasn't changed
Let's clear up the most important thing immediately, because it's the question on most women's minds: the rename does not change your diagnosis, your symptoms, or your treatment.
If you have PCOS, you have PMOS - they are the same condition. The diagnostic criteria are unchanged. The way it's managed is unchanged. Your medical records, your test results, and your care all carry on exactly as before. Over the coming months and years, both names will appear side by side in clinics, lab reports, and patient materials as the new term gradually becomes standard. You don't need to do anything, and nothing about your health has shifted because of this announcement.
So if you found this article slightly alarmed by the headlines - you can relax. This is a change of language, not a change of condition.
Insight
A name change can feel unsettling when it's about your own health. But this one is good news: it doesn't mean your condition is different or more serious - it means the medical world has finally given it a name that reflects what it actually is.
What the new name actually is
The new name is Polyendocrine Metabolic Ovarian Syndrome, or PMOS. It's worth breaking down, because every word was chosen deliberately to describe the condition more accurately than "polycystic ovary syndrome" ever did:
- Polyendocrine - meaning it involves multiple hormone-producing (endocrine) systems: not just the ovaries, but the adrenal glands, the thyroid, and the pancreas (which produces insulin).
- Metabolic - placing the metabolic dimension of the condition front and centre, where it belongs.
- Ovarian - acknowledging the ovarian involvement that remains part of the picture.
- Syndrome - a collection of related features that occur together.
Compare that to the old name. "Polycystic ovary syndrome" put the entire emphasis on cysts and ovaries - and that emphasis turned out to be misleading.
Why the name was changed
This wasn't a hasty or arbitrary decision. The change was published in The Lancet in May 2026 and presented at the European Congress of Endocrinology, capping one of the most thorough renaming processes in medical history - a 14-year global consensus involving 56 patient and professional organisations and around 22,000 patients, doctors, and researchers across the world.
There's a detail here that should make every Australian woman with this condition take notice: the global effort was led by Professor Helena Teede of Monash University, right here in Australia. This was an Australian-led change to how a condition affecting 170 million women worldwide is named and understood. That's a significant piece of Australian women's-health leadership.
So why change a name that had stood for nearly 90 years? Two core reasons.
Reason one: "cysts" was misleading. Despite the old name, many women diagnosed with the condition don't actually have ovarian cysts at all. What appears on an ultrasound isn't true cysts but immature follicles that haven't released eggs - and a large proportion of women meet the diagnostic criteria without any ovarian changes showing on a scan. Naming the condition after cysts that many patients don't have led to confusion, missed diagnoses, and women being told they "couldn't" have the condition because their ovaries looked normal.
Reason two - and this is the important one: the old name hid the metabolic nature of the condition. When a condition is named after the ovaries, that's where clinical attention goes. The name shaped the workup - investigations focused on the reproductive system while the metabolic drivers underneath went unscreened. The result, repeated across decades, was women whose insulin resistance, blood sugar dysregulation, and metabolic dysfunction were overlooked because everyone was looking at the wrong organ.
Insight
The whole point of the rename is to move attention from the ovaries to the metabolism. As the experts behind the change put it, when the word in front of a clinician says "ovary," the lab tests tend to follow the ovary - and the metabolic screening that these women genuinely need gets skipped.
Why this change matters so much - and why we welcome it
Here's where this becomes more than a piece of news, and why this site in particular has watched the change with real interest.
Everything we've ever written here is built on one central idea: that PCOS - now PMOS - is fundamentally a metabolic condition, and that treating it as purely a reproductive or hormonal problem misses the engine driving most women's symptoms. We've made that case across every article: that insulin resistance drives most PCOS symptoms, that the hormonal imbalance is downstream of a metabolic one, and that even normal-weight women have significant metabolic involvement that standard care routinely overlooks.
The rename to Polyendocrine Metabolic Ovarian Syndrome is, in effect, the global medical community formally agreeing with that framing. The new name leads with hormones and metabolism precisely because the evidence now overwhelmingly shows that's where the condition lives. Indeed, research confirms insulin resistance is present in the majority of women with the condition - including many who aren't overweight.
For the women who've spent years being told their bloods were "normal," who were handed the pill or generic advice and sent away, who instinctively felt their condition was about their whole body and not just their ovaries - the new name is a validation. You were right. The science and the language have finally caught up.
What this means for how you should think about your condition
If the rename does one useful thing for you personally, let it be this: it's an invitation to stop thinking about your condition as an ovary problem and start thinking about it as a metabolic one. That shift changes what actually helps.
When PMOS is understood as the metabolic condition it is, the most effective interventions become clear. It's not primarily about managing individual symptoms - the irregular cycles, the acne, the weight, the fatigue - as separate issues. It's about addressing the metabolic dysfunction underneath them, which tends to improve the whole picture at once. The single most powerful lever for most women is stabilising blood sugar and lowering the chronic insulin load through nutrition, which is why knowing whether insulin resistance is part of your picture is such a useful starting point.
And because the metabolic response to food differs from one woman to the next, the most effective nutritional approach is a personalised one - built around your individual biochemistry rather than a generic "PCOS diet." This is now well established in nutrition science, and it's the principle behind the personalised metabolic and nutrition programmes that produce the strongest results: identifying the specific foods that calm your insulin response and support your metabolism, rather than applying a one-size-fits-all template. The rename simply makes the case for that metabolic, personalised approach more clearly than ever.
A quick note on terminology on this site
You'll notice we still use "PCOS" across much of this site, often alongside "PMOS." That's deliberate, for now. The new name is rolling out gradually, and "PCOS" remains the term most women know and search for. As the transition progresses, you'll see both terms used together - PCOS (now known as PMOS) - so that whichever term you're familiar with, you'll find the information you're looking for. The condition, and our approach to it, remains exactly the same.
Clinical Insight
The renaming of polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome represents a substantive conceptual correction rather than a cosmetic relabelling, and its clinical significance lies in the reorientation of diagnostic and therapeutic attention that it is intended to produce. The former terminology was problematic on two counts: first, it centred a morphological feature - ovarian "cysts," more accurately arrested antral follicles - that is neither universally present nor required for diagnosis under the Rotterdam criteria, contributing to under-recognition in women without ultrasonographic ovarian changes; and second, by foregrounding the ovary it systematically directed clinical workup toward the reproductive axis while the condition's metabolic and broader endocrine features went unscreened.
The revised nomenclature explicitly names the polyendocrine involvement - ovarian, adrenal, thyroidal, and pancreatic - and elevates the metabolic dimension, reflecting the now well-established evidence base that insulin resistance and compensatory hyperinsulinaemia are present in the majority of affected individuals across both higher-weight and lean phenotypes, and that the condition carries substantial cardiometabolic risk independent of reproductive features.
The practical implication for care is a shift toward routine metabolic assessment - including direct measurement of insulin rather than glycaemia alone - and toward intervention targeting the underlying metabolic driver, since improvement in insulin sensitivity is associated with concurrent benefit across the reproductive, dermatological, and metabolic symptom domains.
The diagnostic criteria and management protocols are not altered by the renaming, and adoption will be incremental, with both terms in concurrent use during the transition; however, the reframing is expected, over time, to reduce diagnostic delay and to normalise the metabolic screening and individualised nutritional intervention that the evidence has long supported but that the previous ovary-centric framing tended to obscure.
Working With PMOS - Treating It As the Metabolic Condition It Is?
The rename to Polyendocrine Metabolic Ovarian Syndrome confirms what underpins every programme I run: that this is, at its core, a metabolic condition - and that addressing the metabolic drivers is what shifts the whole picture. My metabolic health programmes begin with a comprehensive analysis of your individual blood chemistry, looking well beyond standard screening at what's actually happening with your insulin and metabolism, then build a personalised nutrition plan around your biochemistry - identifying the specific foods that calm your insulin response and support your hormones.
Many women describe this as the first time their condition was treated as the whole-body, metabolic issue it is - rather than as an ovary problem managed one symptom at a time.
👉 Book a 1:1 Health Strategy Session
In-clinic and remote consultations available.
Free resource
Download the 7-Day Metabolic Reset Guide - whether you call it PCOS or PMOS, the metabolic foundations are the same. A free, clinically grounded guide to begin stabilising blood sugar and supporting your metabolism this week. No supplement lists. No extreme protocols. Designed specifically for women.
Frequently Asked Questions
Is PMOS the same as PCOS?
Yes. PMOS (polyendocrine metabolic ovarian syndrome) is the new official name for the condition previously called PCOS (polycystic ovary syndrome). It's the same condition - the name has changed, not the diagnosis, symptoms, or treatment.
Why was PCOS renamed to PMOS?
The name was changed for two main reasons: many women with the condition don't actually have ovarian cysts, making the old name misleading; and the term "polycystic ovary syndrome" obscured the condition's metabolic and broader hormonal nature, contributing to missed diagnoses and inadequate metabolic care. The new name reflects that it involves multiple hormone systems and has a central metabolic component.
When did PCOS become PMOS?
The change was announced in May 2026, published in The Lancet, following a 14-year global consensus process led by Professor Helena Teede of Monash University in Australia, involving 56 organisations and around 22,000 patients and professionals.
Do I need to do anything now that PCOS is called PMOS?
No. Your diagnosis, treatment, and care continue exactly as before. Both names will be used together during the transition. Nothing about your health has changed.
Does the name change affect my treatment?
No. Diagnostic criteria and treatment protocols are unchanged. The rename is intended, over time, to encourage better metabolic screening and care - but it doesn't alter how the condition is currently diagnosed or managed.
